---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-041350"
form_type: "8-K"
ticker: null
cik: "0001008848"
company_name: "Acorda Therapeutics, Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:09:32.897418+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acorda Therapeutics receives Nasdaq delisting notice after Chapter 11 filing

## Summary
- Nasdaq will suspend ACOR common stock at open on April 12, 2024, due to Chapter 11 filing and equity shortfall.
- Delisting follows the company's April 1 voluntary Chapter 11 petition and agreement with Merz Therapeutics to acquire substantially all assets.
- Company does not intend to appeal; expects stock to trade on the Pink Open Market after suspension.
- Nasdaq cited noncompliance with Listing Rules 5101, 5110(b), IM-5101-1, and failure to maintain at least $10M stockholders' equity.

## SEC filing metadata
- accession: 0000950170-24-041350
- form_type: 8-K
- cik: 0001008848
- company_name: Acorda Therapeutics, Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1008848/000095017024041350/0000950170-24-041350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1008848/000095017024041350/acor-20240403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-041350
- JSON: https://secwatch.observer/filing/0000950170-24-041350.json
- Plain text: https://secwatch.observer/filing/0000950170-24-041350.txt

## Key facts
- Listing & Compliance Notices
  Acorda Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101, 5110(b), IM-5101-1
  source text: April 3, 2024, the Company was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the “Common Stock”) from Nasdaq. Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of the Chapter 11 Case. Nasdaq also notified the Company, as a separate basis for delisting, that the Company was not in compliance with Listin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1008848/000095017024041350/0000950170-24-041350-index.htm
- Listing & Compliance Notices
  Acorda Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5450(b)(1)(A)
  source text: April 3, 2024, the Company was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the “Common Stock”) from Nasdaq. Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of the Chapter 11 Case. Nasdaq also notified the Company, as a separate basis for delisting, that the Company was not in compliance with Listin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1008848/000095017024041350/0000950170-24-041350-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.